INCLUNOX HP SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

ENOXAPARIN SODIUM

제공처:

SANDOZ CANADA INCORPORATED

ATC 코드:

B01AB05

INN (International Name):

ENOXAPARIN

복용량:

150MG

약제 형태:

SOLUTION

구성:

ENOXAPARIN SODIUM 150MG

관리 경로:

INTRAVENOUS

패키지 단위:

15G/50G

처방전 유형:

Prescription

치료 영역:

HEPARINS

제품 요약:

Active ingredient group (AIG) number: 0131860002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2020-11-05

제품 특성 요약

_Inclunox _
_Page 1 of 73_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
INCLUNOX
®
Enoxaparin sodium solution for injection, 100 mg/mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
(Subcutaneous or Intravenous Use Only)
Pr
INCLUNOX
® HP
Enoxaparin sodium solution for injection, 150 mg/mL (High Potency)
120 mg/0.8 mL
150 mg/mL
(Subcutaneous or Intravenous Use Only)
Anticoagulant/Antithrombotic Agent
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, Quebec
J4B 1E6
Date of Initial Approval:
November 5, 2020
Submission Control No: 233987
_ _
_Inclunox _
_Page 2 of 73_
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................4
1
INDICATIONS
....................................................................................................................4
Pediatrics
..............................................................................................................................4
Geriatrics
..............................................................................................................................4
2
CONTRAINDICATIONS ..................................................................................................5
3
DOSAGE AND ADMINISTRATION ...............................................................................5
3.1
Dosing Considerations
...............................................................................................5
3.2
Recommended Dose and Dosage Adjustment
...........................................................5
3.3
Administration
...........................................................................................................8
3.4
Missed Dose
.............................................................................................................10
4
OVERDOSAGE ........................................................